State Street SPDR S&P Pharmaceuticals ETF
XPH
78 hedge funds and large institutions have $308M invested in State Street SPDR S&P Pharmaceuticals ETF in 2014 Q4 according to their latest regulatory filings, with 15 funds opening new positions, 32 increasing their positions, 21 reducing their positions, and 10 closing their positions.
52% more repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 21
50% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 10
8% more capital invested
Capital invested by funds: $286M → $308M (+$22.6M)
5% more funds holding
Funds holding: 74 → 78 (+4)
0.29% less ownership
Funds ownership: 59.26% → 58.97% (-0.29%)
42% less call options, than puts
Call options by funds: $497K | Put options by funds: $864K
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$5.46M |
| 2 |
VC
Vicus Capital
State College,
Pennsylvania
|
+$4.71M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$2.52M |
| 4 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$2.43M |
| 5 |
Wells Fargo
San Francisco,
California
|
+$2.41M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CA
Cumberland Advisors
Sarasota,
Florida
|
-$4.1M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$1.42M |
| 3 |
Morgan Stanley
New York
|
-$1.24M |
| 4 |
MFS
MSI Financial Services
Springfield,
Massachusetts
|
-$808K |
| 5 |
FAAS
First Allied Advisory Services
San Diego,
California
|
-$622K |
XPH Hedge Fund Activity: Q4 2014 in Review
78 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in State Street SPDR S&P Pharmaceuticals ETF (XPH) for Q4 2014, worth a combined $308M — up 7.9% from $286M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new XPH positions and 10 closed out — a net gain of 5 holders — while 32 added to existing stakes and 21 trimmed.
The largest buyer was Deutsche Bank, adding an estimated $5.46M. The largest seller was Cumberland Advisors, cutting an estimated $4.1M.
- 78 institutional investors held State Street SPDR S&P Pharmaceuticals ETF (XPH) as of Q4 2014, up from 74 in Q3 2014.
- Funds reported $308M of State Street SPDR S&P Pharmaceuticals ETF stock for Q4 2014, up 7.9% quarter-over-quarter.
- 15 funds opened new State Street SPDR S&P Pharmaceuticals ETF positions in Q4 2014 and 10 closed out, a net change of +5 holders.
- The largest State Street SPDR S&P Pharmaceuticals ETF buyer in Q4 2014 was Deutsche Bank, an estimated $5.46M added.
- The largest State Street SPDR S&P Pharmaceuticals ETF seller in Q4 2014 was Cumberland Advisors, an estimated $4.1M sold.
Based on aggregated 13F filings for Q4 2014.